Appendix: Author Biographies
|
|
- Dulcie Amelia McDonald
- 5 years ago
- Views:
Transcription
1 Appendix: Author Biographies Steven R. Alexander, M.D., is Medical Director, Spectrum Operations, Training and Compliance, Stanford Center for Clinical & Translational Education & Research. He is Professor and Chief of Pediatric Nephrology at Stanford University School of Medicine. He earned his M.D. from Baylor College of Medicine. Mark Backer, Ph.D., received a B.S. in Chemistry from Stanford University and a Ph.D. in Chemical Engineering from the University of Washington. He has worked to develop biopharmaceuticals since joining Genentech as its seventh employee in 1978 and has participated in the development of seven commercial products. He is currently General Manager of Alava Biopharm Partners, a consulting group focused on CMC support for product developers. He also supports the SPARK program in an advisory role. Rebecca Begley, Ph.D., is an Associate Manager for Regulatory Project Management at Gilead Sciences. Prior to that, she worked at KAI Pharmaceuticals as a Scientist and Project Manager. She received her undergraduate degree from Barnard College and her Ph.D. from Stanford University in Terrence Blaschke, M.D., is Senior Program Officer, Global Health Discovery and Translational Sciences at the Bill and Melinda Gates Foundation and an emeritus Professor of Medicine in the Division of Clinical Pharmacology at Stanford University School of Medicine. His research interests include clinical pharmacology of drugs used in HIV-infected patients with a particular interest in access and quality of these drugs in less-developed countries. Peter Boyd, Esq., worked as an associate until 2012 in the Silicon Valley office of Latham & Watkins LLP, where he represented start-up companies and venture capitalists. He has also served on the management team of a privately held medical device company. Mr. Boyd earned his B.S. in Biology from UNC-Chapel Hill and a joint J.D. M.B.A. degree from the University of Virginia. D. Mochly-Rosen and K. Grimes (eds.), A Practical Guide to Drug Development in Academia, SpringerBriefs in Pharmaceutical Science & Drug Development, DOI / , The Editors
2 172 Appendix: Author Biographies Jennifer Swanton Brown, R.N., is Manager, Regulatory Services and Education in Operations, Training and Compliance; Spectrum, Stanford Center for Clinical & Translational Education & Research. Liliane Brunner Halbach, Ph.D., is a consultant in the Bay Area and is currently working as a contractor for Genentech. After starting her career in the pharmaceutical industry 17 years ago in the Metabolic Disease Department at Novartis, she continued as a global Market Analyst for Rheumatology at Roche CH. A transfer to Roche Spain gave her the opportunity to work in Business Development, Marketing and Finance. Liliane has a Ph.D. in Pharmacology from the University of Basel, Switzerland. Leon Chen, Ph.D., M.B.A., is a Venture Partner at OrbiMed Advisors, working with the private equity team on venture capital investments. Prior to joining OrbiMed, Leon was a Partner at Skyline Ventures. He was a cofounder of KAI Pharmaceuticals, a company he started with Dr. Daria Mochly-Rosen based on his work as a Ph.D. student in her lab. As a biotech entrepreneur, he has experience in drug discovery, building a research organization and has taken drugs from the laboratory into clinical development. Leon has a Ph.D. in Molecular Pharmacology from Stanford University School of Medicine, and an M.B.A. from the Stanford Graduate School of Business. Eugenio L. de Hostos, Ph.D., M.B.A., works for OneWorld Health, an affiliate of PATH that develops medicines for the neglected diseases of the developing world. In his role as Director of Research and Preclinical Development, Dr. de Hostos manages discovery and preclinical stage projects and is involved in expanding the OneWorld Health portfolio through partnerships with other companies, academic researchers, and donor institutions. Dr. de Hostos received his B.S. in Biology from Yale University in 1983 and his Ph.D. in Biology from Stanford University in In 2010 he completed his M.B.A. in environmentally sustainable and socially responsible business from the Presidio School of Management. Emily Egeler, Ph.D., is the Program Coordinator for the SPARK Translational Research Program at Stanford University School of Medicine, where she helps manage SPARK projects and coordinates outreach with other academic institutions setting up SPARK programs and various other internal and external projects. She received her Ph.D. in Chemical and Systems Biology from Stanford University School of Medicine. Daniel Erlanson received his Ph.D. in Chemistry at Harvard University and completed postdoctoral research at Genentech before joining Sunesis Pharmaceuticals at its inception, where he eventually became Associate Director of Medicinal Chemistry. Dan subsequently cofounded Carmot Therapeutics, Inc., a company that applies proprietary technology to the discovery of small-molecule drugs for unmet medical needs. Nicholas Gaich has more than 35 years of experience in areas such as supply chain management, service line economics, and clinical research infrastructure and operations. He retired in 2012 as Assistant Dean, Clinical and Translational Research
3 Appendix: Author Biographies 173 Operations of the Stanford Center for Clinical and Translational Education and Research and now runs an executive management consulting firm, Nick Gaich and Associates, and serves as a Senior Advisor to the angel investment firm Venture- Med. He received his B.B.A. with an emphasis in Healthcare Administration from National University of San Diego. Harry Greenberg, M.D., is the Joseph D. Grant Professor of Medicine and Microbiology and Immunology and the Senior Associate Dean for Research at Stanford University School of Medicine. He has been an active NIH funded investigator for over 30 years during which time his studies have focused primarily on viruses that infect the GI tract, liver, or respiratory tree. Dr. Greenberg was the Chief Scientific Officer at a biotechnology company called Aviron (now MedImmune Vaccines), where he played an important role in bringing the live attenuated influenza vaccine to licensure. Kevin Grimes, M.D., M.B.A., received his M.D. from Brown University and his M.B.A. from Stanford University. After his training, he joined the Stanford faculty as an academic internist. He later worked in the medical device and biotechnology sectors before returning to academia. He is currently the Co-Director of the SPARK Translational Research Program and Associate Professor of Chemical and Systems Biology at Stanford University School of Medicine, where he also teaches drug discovery and development and the practice of internal medicine. Scott Iyama, Esq., focuses his practice on the representation of early stage technology companies, with a particular focus on life science companies and university spinouts. He is a member of the Emerging Companies Group at Orrick, Herrington & Sutcliffe LLP (Orrick). Prior to attending Stanford Law School, Mr. Iyama performed extensive biological-based research as a graduate student at the University of California San Diego and as a research assistant at Genentech, Inc. and the NASA Ames Research Center. Carol Karp is Senior VP of Regulatory Affairs at Esperion Therapeutics. With over 30 years of experience, Carol has held leadership positions in pharmaceutical and biotechnology companies, maintaining a primary focus on innovative regulatory strategies for the development and commercialization of therapeutics and diagnostics in disease areas including cardiology, metabolic disorders, immunology, Alzheimer s Disease, analgesia, and anesthesia. Kevin Kinsella is a graduate of MIT and the Johns Hopkins School of Advanced International Studies. He founded Avalon in 1983 and has specialized in the formation, financing, and/or development of more than 60 early-stage companies. He currently serves on the Boards of Directors of several Avalon portfolio companies. He is also the largest individual producer of the Tony Award-winning hit Broadway musical, Jersey Boys. He is a member of the Council on Foreign Relations and a member of the Broadway League. Bruce Koch received his Ph.D. in Cell and Developmental Biology from Harvard University and completed his post-doctoral studies at the University of California at Berkeley. He joined the discovery research group at Syntex rising to the position of
4 174 Appendix: Author Biographies Director of Discovery Technologies at Roche Pharmaceuticals. He is currently the Senior Director, Discovery and Technological Service Centers at the Stanford University School of Medicine. Katharine Ku is the director of the Stanford University Office of Technology Licensing and is a registered Patent Agent. She got her B.S. in Chemical Engineering from Cornell University and a Master s in Chemical Engineering from Washington University in St. Louis and has worked at a number of industry and academic institutions. Robert Lum, Ph.D., is a veteran in drug development with experience in both large and small pharmaceutical companies. In the past, he has served as the Executive Director, Process Development and Manufacturing at Geron Corporation; Vice President, Technology and Preclinical Development at Telik, Inc.; Assistant Director of Medicinal Chemistry at CV Therapeutics; and Senior Scientist at Arris Pharmaceutical. He received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. from Massachusetts Institute of Technology. Ted McCluskey, M.D., Ph.D., has over 15 years experience in biotech, pharmaceutical and diagnostic development designing, implementing, and analyzing clinical trials. He has worked in multiple disease areas and participated in four product approvals. Past positions include Chief Medical Officer and VP Clinical at AVIIR, Inc, Senior Director of Clinical Research at SCIOS, and Medical Director at Genentech. He is a board-certified cardiologist (Interventional and Molecular) and received his M.D. and Ph.D. from Washington University in St. Louis. Dr. McCluskey is also active in Sand Hill Angels, serving as its President and on the Board of Directors. Alan Mendelson, Esq., has been a partner at Latham & Watkins LLP s Silicon Valley office since 2000 and is the cochair of the firm s Emerging Companies Practice and Life Sciences Industry Groups. He currently serves as a member of the University of California Board of Regents and the Boards of Trustees of the UC Berkeley Foundation and The Scripps Research Institute, as well as the corporate secretary for many public and private companies. Since 1993, Mr. Mendelson has been listed in editions of The Best Lawyers in America and IPO Vital Signs. He received his A.B. from the University of California, Berkeley, and his J.D. from Harvard University. Daria Mochly-Rosen, Ph.D., is the George D. Smith Professor of Translational Medicine, the Senior Associate Dean for Research, and a Professor in the Department of Chemical and Systems Biology at Stanford University School of Medicine and the Co-Director of SPARK. She received her Ph.D. from the Weizmann Institute of Science in Israel, and was a postdoctoral fellow in the department of biochemistry at the University of California, Berkeley. She joined Stanford University School of Medicine in 1993 and served as the chair of her department for 4 years. In 2003, her lab s basic research led to the founding of KAI Pharmaceuticals, where she served as the CSO for 1 year, and as the chair of the Scientific Advisory Committee and a member of the Board of Directors after her return to
5 Appendix: Author Biographies 175 academia. She also founded ALDEA Pharmaceuticals in In addition, Dr. Mochly-Rosen served on a variety of review groups including the Peer Review Advisory Committee of the NIH and on the Council of Councils of the NIH. Judy Mohr received her Ph.D. in Chemical Engineering from the University of Texas at Austin and her J.D. from Santa Clara University. She has extensive experience working in patent law with an emphasis in pharmaceuticals. Judy is a partner at McDermott Will & Emery LLP (Silicon Valley Office). She also supports the SPARK program in an advisory role. Julie Papanek, M.B.A., is a Market Planning Manager with a number of years experience working in industry. After graduating from Yale University with a B.S. in Molecular Biophysics and Biochemistry, she received an M. Phil. in BioScience Enterprise from Cambridge University and an M.B.A. from Stanford Business School. Her experience in licensing and market assessment spans academic and industry institutions, including 5 years in various positions in Genentech. Christopher M. Reilly, Esq., was a summer associate during 2011 in the Silicon Valley office of Latham & Watkins LLP. He graduated in 2012 from the University of Virginia School of Law and joined Latham s Silicon Valley office in the fall of Werner Rubas, Ph.D., is the founder, President, and CEO of PK/ADME Consulting, LLC. Currently, he holds a Director position at NEKTAR and is responsible for preclinical PK. He has over 25 years of experience working in the pharmaceutical field in academia, start-up, mid-size, and Fortune 500 companies. In 1999 he was the co-recipient of the PHOENIX Pharmazie-Wissenscaftspreis. Dr. Rubas received his Ph.D. and Pharmacist licensure from ETH Zurich. He has served as a SPARK adviser since Steven Schow, Ph.D., is the Vice President of Research and Development at Telik, Inc. He has over 35 years of pharmaceutical, biotech, and agrichemical industrial research and development experience. His work spans a wide range of indications, including psychotropic, anti-infective, cardiovascular, immunological, metabolic, and anticancer R&D, as well as research in novel insecticides. Dr. Schow has been a SPARK advisor and advocate since Michael Taylor, Ph.D., DABT, is the Founder and Principal at Non-Clinical Safety Assessment, a consulting firm specializing in the development of drugs and medical devices. Dr. Taylor has more than 20 years of R&D experience in the pharmaceutical industry and has served on executive teams. He is a board-certified toxicologist and holds Ph.D. and M.S. degrees in Toxicology from Utah State University with postdoctoral training at the NIH and CNRS of France. He has been a SPARK advisor for the past 6 years. Simeon Taylor received a Ph.D. in Biological Chemistry and an M.D. both from Harvard University. He is a board-certified physician in the specialty of Internal Medicine and the subspecialty of Endocrinology & Metabolism. For the majority of
6 176 Appendix: Author Biographies his career, he worked in the Division of Intramural Research in the National Institute of Diabetes and Digestive and Kidney Disease, where he served as Chief of the Diabetes Branch ( ). He has worked in the pharmaceutical industry since 2000, at Eli Lilly ( ) and at Bristol-Myers Squibb (2002-present), where he currently serves as Vice President, Research & Scientific Affairs. During his time at Bristol-Myers Squibb, he led the Cardiovascular and Metabolic Disease Drug Discovery organization, which has advanced more than 25 compounds into development. Stephen Venuto, Esq., focuses on the representation of high growth technology and media companies, their founders and investors. His practice includes the formation, financing, and general corporate counseling of emerging growth private and public companies; representation of venture capital firms and investment banks in private and public offerings; and other complex transactions. He is a member of the Emerging Companies Group at Orrick, Herrington & Sutcliffe LLP (Orrick). Susan Wade has 25 years of industrial experience in the areas of Quality Assurance, Quality Control, and product development for manufacturers of pharmaceuticals and medical devices. She also has extensive experience with aseptic processing, sterile fill, and validation of products including API, proteins, antibodies, traditional pharmaceuticals, viral gene therapy vectors, autologous cell therapies, and orthopedic medical devices. She has global experience with audits, validation, analytical and bioanalytical assay development, as well as development of policies and systems for ISO, QSR, and GMP compliance. John Walker is a biotechnology industry veteran with over 30 years of experience in the healthcare and biopharmaceutical industries. He received a B.A. in History from the State University of New York at Buffalo and is a graduate of the Advanced Executive Program, J. L. Kellogg Graduate School of Management at Northwestern University. Mr. Walker serves as chairman of the boards of directors of Renovis, KAI Pharmaceuticals, Guava Technologies, and Saegis Pharmaceuticals. He serves on the boards of directors for Geron and several privately held biotechnology companies. He also serves as an advisor to the SPARK Program at Stanford.
TRANSLATIONAL SCIENCE
TRANSLATIONAL SCIENCE A Discussion of Best Practices and Unique Models Wednesday January 31, 2018 at The NYSCF Research Institute HRA TRI-STATE REGIONAL MEETING 31 Wednesday January, 2018 AGENDA 8:30 AM
More informationBiotech Concerto #6 Investment Process December 2008
Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision
More informationManagement Team. Bruce C. Cozadd Chairman and Chief Executive Officer
Bruce C. Cozadd Chairman and Chief Executive Officer Bruce Cozadd joined Jazz Pharmaceuticals at its inception and was appointed Jazz Pharmaceuticals Chief Executive Officer in April 2009. From 2003 until
More informationTHE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES
THE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES Join us for a very special program co-hosted the HBS Alumni of Boston (HBSAB), The Harvard Stem Cell Institute (HSCI), and the Harvard NeuroDiscovery
More informationFinal Pitch Competition PROGRAM GUIDE. Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV
Final Pitch Competition PROGRAM GUIDE Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV #HITVenture #HIMSS16 1 Presented by: WEDNESDAY, MARCH
More informationScripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011
Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic
More informationWILSON SONSINI GOODRICH & ROSATI
WILSON SONSINI GOODRICH & ROSATI IS PLEASED TO ANNOUNCE THAT THE FOLLOWING ATTORNEYS HAVE BECOME PARTNERS AT THE FIRM. Troy Foster Corporate & Securities, Palo Alto Jessica L. Margolis Litigation, New
More informationSeptember 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board
AGENDA SPECIAL CALLED TELEPHONE MEETING of THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS September 18, 2017 Austin, Texas Page CONVENE THE BOARD IN OPEN SESSION TO RECESS TO EXECUTIVE SESSION PURSUANT
More informationCelebrating International Women's Day Friday, March 8, :30am-1:00pm
Co-Hosted by: Join us in Launching the 1st Annual Successful Women of San Diego Executive Leadership Panel Celebrating International Women's Day Friday, March 8, 2019 11:30am-1:00pm Sponsored by: Location:
More informationThe MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009
The MoneyTree Report Overview of Venture Capital Investments Third Quarter 2009 PricewaterhouseCoopers/National Venture Capital Association MoneyTree Report based on data from Thomson Reuters 1 Host of
More informationWOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview
Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context
More informationAgenda. Genesys Capital Partners. The Opportunity. Our Approach
MEDT Dinner Presentation September 28, 2005 Agenda Genesys Capital Partners The Opportunity Our Approach Genesys Capital Partners Genesys Capital Partners Successful Track Record Management experience
More informationCASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
More informationInclusion Women at the Forefront of STEM
Innovation and Inclusion Women at the Forefront of STEM Hosted by the Association for Women in Science SPONSORSHIP Innovation and Inclusion: Women at the Forefront of STEM The Association for Women in
More informationGlobal Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner
Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis
More informationReinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &
More informationABRAHAM ABUCHOWSKI, PH.D.
ABRAHAM ABUCHOWSKI, PH.D. Biographical Sketch Dr. Abuchowski is the developer of the current gold standard technology for protein drug delivery called PEGylation. The development of this technology was
More informationWhere the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes
Where the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes Scientific innovation is at the heart of everything we do. Scientific innovation is at the heart of our business and
More informationThe MoneyTree Report. Overview of Venture Capital Investments Second Quarter 2008
The MoneyTree Report Overview of Venture Capital Investments Second Quarter 2008 PricewaterhouseCoopers/National Venture Capital Association MoneyTree Report based on data from Thomson Reuters 1 Host of
More informationgellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp.
gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) 315-0600 Web gellerbp.com Summary Personal Diverse, world-class team of top biotech bankers,
More informationHFMA January CFO Forum
HFMA January CFO Forum January 26, 2018 St. Mark s Hospital Education Auditorium 1200 E. 3900 S. Salt Lake City, Utah 7.0 CPE hours 7:30 8:00 a.m. Continental Breakfast 8:00 8:15 a.m. Opening and Chapter
More informationLISA TILTON-McCARTHY
LISA TILTON-McCARTHY Lisa Tilton-McCarthy received a B.A. in English from Texas A&M University in College Station and graduated summa cum laude from South Texas College of Law in Houston. She was Editor-in-Chief
More informationLife Sciences Queensland announces latest LSQ Ambassadors
MEDIA RELEASE Monday 22 April, 2013 FOR IMMEDIATE RELEASE Life Sciences Queensland announces latest LSQ Ambassadors (LSQ) is pleased to announce our latest LSQ Ambassadors - two of the life sciences industry
More informationDean A. Connor. President & Chief Executive Officer, Sun Life Financial
Dean A. Connor President & Chief Executive Officer, Sun Life Financial Dean A. Connor was appointed President & Chief Executive Officer, Sun Life Financial on December 1, 2011, and is a member of the company
More informationLIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationPANEL DISCUSSION & ROUNDTABLES
LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the
More informationBorn Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016.
Board of Directors Håkan Björklund Chairman Born 1956. Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016. Other appointments: Currently serves as Industry Executive at Avista Capital
More informationExperiences of an aspiring young scientist-entrepreneur
Experiences of an aspiring young scientist-entrepreneur Francis W. Hunter Auckland Cancer Society Research Centre Spark Entrepreneurship Challenge Mesopharm Therapeutics, Inc. 5 May 2014 Background Auckland
More informationNMB NATIONAL MEDIATION BOARD LINDA A. PUCHALA HARRY R. HOGLANDER
7 LINDA A. PUCHALA CHAIRMAN Chairman Linda A. Puchala was first confirmed as Member of the National Mediation Board by the United States Senate on May 21, 2009. She was sworn into office on May 26, 2009.
More informationRegional Innovation Ecosystems:
Regional Innovation Ecosystems: The Role of the University in Fostering Economic Growth Ross DeVol Chief Research Officer Milken Institute Caltech Giant High Level Forum, Leading Innovation Ecosystems
More informationJOHN JACK R. TUPMAN, JR CURRICULUM VITAE
JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant
More informationGlobal Pharmaceuticals
ROSENFIELD PR OGR AM in public affairs, international relations, and human rights Global Pharmaceuticals February 3 5, 2009 GRINNELL COLLEGE Global Pharmaceutical Symposium February 3-5, 2009 Tuesday,
More informationEligibility Criteria Created Sunday, November 09, 2014
Eligibility Criteria Created Sunday, November 09, 2014 Please review each eligibility criteria below. Please check the box if you are in compliance with each criteria. Ineligible applicants will not be
More informationRichard J. Donoghue Senior Vice President for Strategy, Planning and Business Development
Richard J. Donoghue Senior Vice President for Strategy, Planning and Business Development Richard (Rick) J. Donoghue, senior vice president for strategy, planning and business development at NYU Langone
More informationMENTORS REGULATORY AFFAIRS. Christophe AMIEL Head of Medical Device & Digital, Voisin Consulting Life Sciences STRATEGY/BUSINESS
Hosted by : INNOLABS IDEAS CONTEST 21 st -22 nd June, Paris MENTORS REGULATORY AFFAIRS Christophe Amiel is heading the design and operational implementation of international regulatory strategies as Senior
More informationAssociate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive
Job Title Alliance Lead Analytics Specialist Associate Director Associate Director Diagnostics Partnering Associate Director Business Development Associate Director Application Architecture Associate Manager
More informationSRII SRII Management Team
SRII Management Team SRII President: Kris Singh, IBM Services Research Kris Singh is the Director of Strategic Programs for Service Research at IBM Almaden Research Center in San Jose, CA. Kris has over
More informationWomen in Innovation: Business and Commerce
Women in Innovation: Business and Commerce Moderator: Judith C. Giordan Organizer: Janet L. Bryant Boston Convention & Exhibition Center, Room 51 August 18, 2015 1:30pm 4:00pm 0 Thank you to Our ACS and
More informationTeresa V. Pahl Partner
Teresa represents clients in all phases and aspects of their businesses. Teresa s expertise includes matters involving general corporate law, securities law and real property law. Teresa works with early-stage
More informationQI Comes of Age: Health Reform Accelerates
12 th Annual ATP Alumni Conference QI Comes of Age: Health Reform Accelerates February 15-17, 2017 At Newpark Resort in Park City, Utah 2009 ATP Alumni Conference. February 10-12, 2010, Newpark Resort,
More informationOmeros Raises More Than $63 Million in Financing
Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,
More informationBaxter 2007 Investor Conference March 14, 2007
Joy A. Amundson is a corporate vice president of Baxter Healthcare Corporation and president of the company s BioScience business. In this position, she is responsible for the development and worldwide
More informationWilliam Rastetter. Interview conducted by. Mark Jones, PhD. July 28, 1997
William Rastetter Interview conducted by Mark Jones, PhD July 28, 1997 Interview conducted by Mark Jones, PhD, on June 4, 1997 William Rastetter Dr. William H. Rastetter, Bill, Ph.D., co-founded Receptos,
More informationBOARD OF DIRECTORS. PETER WEHRLY Chair
BOARD OF DIRECTORS PETER WEHRLY Chair Peter Wehrly is the former group president of developed markets at Covidien, the manufacturer of medical devices with sales of over $10.7 billion (2014). Peter held
More informationNVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations
February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and
More informationChemistry Career Night, 2011
Chemistry Career Night, 2011 Sponsored and organized by the St Louis Section Younger Chemist Committee (YCC) For young chemists in search of career-planning guidance, the Lab Science Building at Washington
More informationYevo Scientific Advisory Board
TM Yevo Scientific Advisory Board Dr. Stacey J. Bell Head of the Yevo Scientific Advisory Board Dr. Stacey Bell has been a nutritional consultant from 2008 to 2014, when she joined Yevo International.
More informationTransforming the right molecules into the best medicines TM
August 2017 Transforming the right molecules into the best medicines TM We are passionate in our mission to improve the health of patients by providing novel strategic alternatives to companies wishing
More informationSteve Hamilton, J.D., CLU, ChFC Director, Advanced Consulting Group Nationwide
Steve Hamilton, J.D., CLU, ChFC Director, Advanced Consulting Group Nationwide Email: hamils25@nationwide.com Direct: 614.249.0935 Steve has over 30 years of experience in the financial services industry.
More informationKoen Dejonckheere. Professional experience. Board Memberships. Education
Koen Dejonckheere Professional experience KBC SECURITIES GROUP 2002-2008 Managing Director, responsible for Corporate Finance Previously, Koen Dejonckheere was active in Corporate Finance and Private Equity
More informationBREAKTHROUGH CONVENTION SUMMARY JUNE SAN DIEGO CONVENTION.BIO.ORG #BIO2017
BREAKTHROUGH CONVENTION SUMMARY JUNE 19-22 SAN DIEGO CONVENTION.BIO.ORG #BIO BIO BY THE NUMBERS FEATURING SEVERAL THEMATIC EXHIBITS 16,123 ATTENDEES 74 48 COUNTRIES STATES 18,000 MORE THAN EXHIBITORS 41,400
More informationDouglas Richman. Interview conducted by. Mark Jones, PhD. August 4, 1997
Douglas Richman Interview conducted by Mark Jones, PhD August 4, 1997 Interview conducted by Matthew Shindell, Historian, UCSD on June 27, 2008 Douglas Richman Dr. Douglas D. Richman, MD is Professor of
More informationForm FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.
Form 51-102FI SERNOVA CORP. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. The following discussion and analysis should be
More informationJURY BOARD BUSINESS/INVESTMENT. Pascal BECACHE Founding President, PBS, Healthcare Industry STRATEGY/BUSINESS
Hosted by : Pascal BECACHE Founding President, PBS, Healthcare Industry INNOLABS IDEAS CONTEST 21 st -22 nd June, Paris JURY BOARD BUSINESS/INVESTMENT Pascal is a seasoned executive with GM and Sales VP
More informationManagement to Host Conference Call at 8:30 a.m. ET today
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),
More informationIgor Fisch. New candidate, independent
Igor Fisch New candidate, independent Igor Fisch is a co-founder of Selexis SA, a biotech company based in Switzerland. He grew the company from inception to profits in less than 5 years with up to > 5MCHF
More informationViking Advisory Group. Company Presentation September 2011
Viking Advisory Group Company Presentation September 2011 Viking Advisory Group Mission To offer value added, high quality services within the disciplines of financial management, accounting, legal, insurance,
More informationDIRECTORS EDUCATION PROGRAM
DEP 71 MODULE III DIRECTORS EDUCATION PROGRAM FACULTY BIOGRAPHIES National Academic Director Richard C. Powers M.B.A. (Queen's University), L.LB. (Queen's University), ICD.D Profit Governance Essentials
More informationTHE REGIONAL ECONOMIC BRIEFING FEDERAL RESERVE BANK OF NEW YORK SPEAKERS BIOGRAPHIES AT THE 33 LIBERTY STREET NEW YORK, NY
THE REGIONAL ECONOMIC BRIEFING AT THE FEDERAL RESERVE BANK OF NEW YORK SPEAKERS BIOGRAPHIES FEDERAL RESERVE BANK OF NEW YORK 33 LIBERTY STREET NEW YORK, NY 10045 WWW.NEWYORKFED.ORG MONDAY, FEBRUARY 14,
More informationRevenue of $100 million to $1 billion and EBITDA in excess of $20 million
NEWSTONE CAPITAL PARTNERS, LLC invests in mezzanine securities of larger middle-market companies involved in leveraged buyouts, recapitalizations, and later-stage growth financings. For the last 20 years,
More informationSPEAKERS A S H A B A N G A L O R E
SPEAKERS ASHA BANGALORE Vice President Economist Asha has been an economist with Northern Trust since 1994. Prior to joining Northern Trust, she was a consultant to savings and loan institutions and commercial
More informationKate Pretty Lecture Thursday 8 March Pascal Soriot, CEO AstraZeneca. What Science Can Do The Cambridge Cluster at a Pivot Point
Kate Pretty Lecture Thursday 8 March 2018 Pascal Soriot, CEO AstraZeneca What Science Can Do The Cambridge Cluster at a Pivot Point Introduction Thank you for your invitation and warm welcome to Homerton
More informationSPEAKER BIOGRAPHIES. Sarah Abbas
SPEAKER BIOGRAPHIES Sarah Abbas Sarah Abbas currently supports global medical education through collaboration with Pfizer Country Offices. She developed and managed the WW Investigator Initiated Research
More informationILLINOIS MATHEMATICS AND SCIENCE ACADEMY
ILLINOIS MATHEMATICS AND SCIENCE ACADEMY igniting and nurturing creative, ethical, scientific minds that advance the human condition Remarks by Sheila MB Griffin Commencement 5/30/15 Class of 2015 Good
More informationComprehensive Research Services
Comprehensive Research Services Scripps Health: At the Forefront of Clinical Research Scripps Health is a recognized leader in clinical research and has long been at the forefront of numerous medical breakthroughs.
More informationMedTech Alliance Program Spring Meeting
Oregon Health & Science University Presents: MedTech Alliance Program Spring Meeting OHSU will be hosting its second MedTech Alliance program meeting on Wednesday, May 6 from 5:00PM to 7:30PM. Community
More informationTHE REGIONAL ECONOMIC BRIEFING FEDERAL RESERVE BANK OF NEW YORK SPEAKERS BIOGRAPHIES AT THE 33 LIBERTY STREET NEW YORK, NY
THE REGIONAL ECONOMIC BRIEFING AT THE FEDERAL RESERVE BANK OF NEW YORK SPEAKERS BIOGRAPHIES FEDERAL RESERVE BANK OF NEW YORK 33 LIBERTY STREET NEW YORK, NY 10045 WWW.NEWYORKFED.ORG THURSDAY, JULY 22, 2010
More informationNektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationMSLOC - Global Thought Leader Roundtable ERIC N. FRIDMAN
ERIC N. FRIDMAN Assistant Dean and Director of Marketing for Executive Education, Northwestern University s Kellogg School of Management Eric Fridman is Assistant Dean and Director of Marketing for Executive
More informationPersonnel. Internal Staff. Scott MacKillop CHIEF EXECUTIVE OFFICER. First Ascent Asset Management
First Ascent Asset Management Personnel Internal Staff Scott MacKillop CHIEF EXECUTIVE OFFICER Scott has worked in the financial services industry for 40 years. He began his career in 1976 as a lawyer
More informationMorowitz Gaming Advisors, LLC presents GAMES. Gaming Management Executive Series
Morowitz Gaming Advisors, LLC presents GAMES Gaming Management Executive Series Detailed Instructor Biographies September 2008 through June 2009 Instructors for Morowitz Gaming Advisors, LLC Cory Morowitz,
More informationRevenue of $100 million to $1 billion and EBITDA in excess of $20 million
NEWSTONE CAPITAL PARTNERS, LLC invests in mezzanine securities of larger middle-market companies involved in leveraged buyouts, recapitalizations, and later-stage growth financings. For the last 20 years,
More informationLehigh University Team biographies. October 30, 2017
Lehigh University Team biographies October 30, 2017 Core team members 2 Lane McBride Partner and Managing Director, Washington, DC Lane McBride is a Partner and Managing Director in the Washington, D.C.
More informationFall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE
Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number
More informationCHC Advisory Board. Commonwealth Honors College Advisory Board. Published on Commonwealth Honors College (
Published on Commonwealth Honors College (https://www.honors.umass.edu) Home > Printer-friendly PDF > Alumni Advisory Board CHC Advisory Board The Commonwealth Honors College Advisory Board is composed
More informationAdditional information about Turner Investments, L.P. is available on the SEC s website at
Form ADV Part 2B Brochure Supplement John P. Fraunces, Jr. Christopher K. McHugh Peter J. Niedland, CFA Jason D. Schrotberger, CFA Scott C. Swickard, CFA Mark D. Turner Robert E. Turner, CFA Turner Investments,
More informationRICHARD BUTLAND Director
RICHARD BUTLAND Richard Butland is the managing partner of Kite Capital, a growth oriented private investment firm. Prior to establishing Kite Capital, Richard spent 15 years at Goldman Sachs where he
More informationGoverning Board. Peter Agre. Pedro Alonso
Governing Board Peter Agre Peter Agre is currently Director of Johns Hopkins Malaria Research Institute Bloomberg School of Public Health. A native Minnesotan, Peter Agre studied chemistry at Augsburg
More informationIndiana University School of Public and Environmental Affairs Dean s Council Members. David Wang, Chair
Indiana University School of Public and Environmental Affairs Dean s Council Members David Wang, Chair David Wang is a Senior Operating Partner of Atlas Holdings, a private equity investment firm that
More informationMr. Smith Chairman, President, and Chief Executive Officer Southern Bank
Mr. Smith has been chairman, president, and chief executive officer of Southern Bank since 1992. Mr. Smith has 38 years of banking experience and served as president of Alabama Bank from 1980 to 1991.
More informationOPEN SESSION. *Some of the business to be conducted is authorized by the N.C. Open Meetings Law to be conducted in closed session.
FOR INFORMATION ONLY (No formal action is requested at this time) OPEN SESSION 1. HIV/AIDS Cure Partnership between GlaxoSmithKline & UNC-CH David Routh, Vice Chancellor for University Development Mark
More informationOther appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT.
Executive Committee Guido Oelkers Chief Executive Officer Born 1965. Employed since 2017. PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London,
More informationNORTH AUSTIN II WILKE LANE PFLUGERVILLE, TX 78660
NORTH AUSTIN II 19447 WILKE LANE PFLUGERVILLE, TX 78660 Erik Carlson, BRE#1347649 Senior Advisor and Vice President 408.392.8822 erik.carlson@svn.com CalBRE #1347649 Paul Getty, BRE#01705899 President
More informationMark-Up Disclosure Requirements Thursday, September 14 2:15 p.m. 3:15 p.m.
Mark-Up Disclosure Requirements Thursday, September 14 2:15 p.m. 3:15 p.m. This session focuses on FINRA and MSRB mark-up disclosure requirements. Panelists discuss securities covered by the new rule,
More informationMara H. Rogers, Partner Norton Rose Fulbright
Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers
More informationANNUAL GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES
ANNUAL GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES The following items on the agenda of the meeting shall be discussed and/or put to a vote. The numbers in the list correspond to the numbers on the
More informationCURRICULUM VITAE PATRICIA E. (STEWART) GUSSIN
CURRICULUM VITAE PATRICIA E. (STEWART) GUSSIN ADDRESS: Longboat Key, Florida Amagansett, NY 11930 E-Mail: gussins@oceanviewpub.com Facebook: www.facebook.com/patricia.gussin PLACE OF BIRTH: Grand Rapids,
More informationInternational Law 12/1/2017. GO PREMIUM
International Law GO PREMIUM www.abaforlawstudents.com/gopremium For just $25 per year, ABA law student members can save on law school necessities and resources from companies like: Students can save more
More informationPerspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond
Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,
More information2017 Author Biographies
2017 Author Biographies Rouget F. (Ric) Henschel Chapter 1: The State of the Law of Claim Construction and Infringement Rouget F. (Ric) Henschel is a partner at Foley & Lardner LLP. He is a member of the
More informationwhen it comes to law OPERATIONAL EXPERIENCE Soody Tronson Managing Founder Phone Fax Woodside / Santa Clara
when it comes to law Soody Tronson Managing Founder OPERATIONAL EXPERIENCE soody@stlgip.com Phone 650.275.3913 Fax 866.325.7964 Woodside / Santa Clara www.stlgip.com matters By appointment only https://calendly.com/soody
More informationWebinar: Perspectives on Board Evaluation Best Practices. March 1, 2018
Webinar: Perspectives on Board Evaluation Best Practices March 1, 2018 Webinar Housekeeping To ask a question during the webinar, please click the chat button. Questions submitted will be answered throughout
More informationTrends in Healthcare Investments and Exits 2018
Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview
More informationGenerex Announces Appointment of Executive Management Team
Generex Announces Appointment of Executive Management Team Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth MIRAMAR, FL, November 15, 2018 -- Generex Biotechnology Corporation
More informationEQUITY STRUCTURES FOR HIGH GROWTH ENTREPRENEURIAL VENTURES
I. Introduction EQUITY STRUCTURES FOR HIGH GROWTH ENTREPRENEURIAL VENTURES Authored By Philip N. Krause Two categories of entrepreneurial ventures: Revenue Model Growth Model this is what we are discussing
More informationExecutive Leadership. Brian D. McAuley Chairman
Executive Leadership Brian D. McAuley Chairman Brian is a world class entrepreneur with extensive experience in start-up businesses. Most recently he was President and CEO of NeoWorld Communications since
More informationEmcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationDISCOVERY LECTURE SERIES
DISCOVERY LECTURE SERIES 2015 The Discovery Lecture Series is designed to introduce scientific and mathematical research to our students. Guest lectures have agreed to share their knowledge and expertise
More informationChristine Clemens, Esq. Finkelstein & Partners, LLP 1279 Route 300, P.O. Box 1111 Newburgh, NY
Christine Clemens, Esq. Finkelstein & Partners, LLP 1279 Route 300, P.O. Box 1111 Newburgh, NY 12551 cclemens@lawampm.com (646) 253-4762 Christine Khalili-Borna Clemens joined the firm in October 2012
More informationFEBRUARY 9-11, Beyond the Basics
FEBRUARY 9-11, 2018 Beyond the Basics On behalf of the students, staff, and faculty here in the Edward P. Fitts Department of Industrial and Systems Engineering at NC State, I would like to welcome you
More information